Persistent Corneal Epithelial Defects (PCEDs) Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Kiora Pharmaceuticals, Inc., Xequel Bio, Kala Pharmaceuticals, Am

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Persistent Corneal Epithelial Defects pipeline constitutes 5+ key companies continuously working towards developing 5+ Persistent Corneal Epithelial Defects treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Persistent Corneal Epithelial Defects Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Persistent Corneal Epithelial Defects Market.

The Persistent Corneal Epithelial Defects Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Persistent Corneal Epithelial Defects Pipeline Report: https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Persistent Corneal Epithelial Defects treatment therapies with a considerable amount of success over the years.
• Persistent Corneal Epithelial Defects companies working in the treatment market are Kiora Pharmaceuticals, Inc., Xequel Bio, Kala Pharmaceuticals, Amber Ophthalmics, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others, are developing therapies for the Persistent Corneal Epithelial Defects treatment
• Emerging Persistent Corneal Epithelial Defects therapies in the different phases of clinical trials are- KIO-201, iNexin, KPI-012, Nexagon, ST266, RGN-259, REC-0559, and others are expected to have a significant impact on the Persistent Corneal Epithelial Defects market in the coming years.
• In August 2023, The AMB-01-006 (NEXPEDE-1) research has enrolled its first patient, according to Amber Ophthalmics Inc. A Phase 2/3 clinical trial (NCT05966493) with random assignment, double masking, and vehicle control is called NEXPEDE-1. Its goal is to assess two lufepirsen ophthalmic gel (Nexagon) doses for the treatment of persistent corneal epithelial defects (PCED).
• In June 2020, A Phase II randomized, prospective, double-masked, vehicle-controlled study was started by Amber Ophthalmics, Inc. to evaluate the safety and effectiveness of topically applying Nexagon® (NEXAGON) to patients who had severe ocular chemical and/or thermal injuries that resulted in corneal persistent epithelial defects.

Persistent Corneal Epithelial Defects Overview
Through tight connections between adjacent cells, the multilayered corneal epithelium protects the eye from infectious agents and keeps its smooth surface intact by continuously renewing cells in the basal cell layer.

Get a Free Sample PDF Report to know more about Persistent Corneal Epithelial Defects Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Persistent Corneal Epithelial Defects Drugs Under Different Phases of Clinical Development Include:
• KIO-201: Kiora Pharmaceuticals, Inc.
• iNexin: Xequel Bio
• KPI-012: Kala Pharmaceuticals
• Nexagon: Amber Ophthalmics
• ST266: Noveome Biotherapeutics
• RGN-259: RegeneRx Biopharmaceuticals
• REC-0559: Recordati Rare Diseases/Mimetech

Persistent Corneal Epithelial Defects Route of Administration
Persistent Corneal Epithelial Defects pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Persistent Corneal Epithelial Defects Molecule Type
Persistent Corneal Epithelial Defects Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Persistent Corneal Epithelial Defects Pipeline Therapeutics Assessment
• Persistent Corneal Epithelial Defects Assessment by Product Type
• Persistent Corneal Epithelial Defects By Stage and Product Type
• Persistent Corneal Epithelial Defects Assessment by Route of Administration
• Persistent Corneal Epithelial Defects By Stage and Route of Administration
• Persistent Corneal Epithelial Defects Assessment by Molecule Type
• Persistent Corneal Epithelial Defects by Stage and Molecule Type

DelveInsight's Persistent Corneal Epithelial Defects Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Persistent Corneal Epithelial Defects product details are provided in the report. Download the Persistent Corneal Epithelial Defects pipeline report to learn more about the emerging Persistent Corneal Epithelial Defects therapies at:
https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Persistent Corneal Epithelial Defects Therapeutics Market include:
Key companies developing therapies for Persistent Corneal Epithelial Defects are - OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, and others.

Persistent Corneal Epithelial Defects Pipeline Analysis:
The Persistent Corneal Epithelial Defects pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Persistent Corneal Epithelial Defects with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Persistent Corneal Epithelial Defects Treatment.
• Persistent Corneal Epithelial Defects key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Persistent Corneal Epithelial Defects Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Persistent Corneal Epithelial Defects market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Persistent Corneal Epithelial Defects drugs and therapies-
https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Persistent Corneal Epithelial Defects Pipeline Market Drivers
• Increasing Research and Development Activities, advancements in Understanding of Disease are some of the important factors that are fueling the Persistent Corneal Epithelial Defects Market.

Persistent Corneal Epithelial Defects Pipeline Market Barriers
• However, lack of Universal Guidelines regarding disease diagnosis and treatment, adverse Effects in the current treatment options and other factors are creating obstacles in the Persistent Corneal Epithelial Defects Market growth.

Scope of Persistent Corneal Epithelial Defects Pipeline Drug Insight
• Coverage: Global
• Key Persistent Corneal Epithelial Defects Companies: Kiora Pharmaceuticals, Inc., Xequel Bio, Kala Pharmaceuticals, Amber Ophthalmics, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others
• Key Persistent Corneal Epithelial Defects Therapies: KIO-201, iNexin, KPI-012, Nexagon, ST266, RGN-259, REC-0559, and others
• Persistent Corneal Epithelial Defects Therapeutic Assessment: Persistent Corneal Epithelial Defects current marketed and Persistent Corneal Epithelial Defects emerging therapies
• Persistent Corneal Epithelial Defects Market Dynamics: Persistent Corneal Epithelial Defects market drivers and Persistent Corneal Epithelial Defects market barriers

Request for Sample PDF Report for Persistent Corneal Epithelial Defects Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Persistent Corneal Epithelial Defects Report Introduction
2. Persistent Corneal Epithelial Defects Executive Summary
3. Persistent Corneal Epithelial Defects Overview
4. Persistent Corneal Epithelial Defects- Analytical Perspective In-depth Commercial Assessment
5. Persistent Corneal Epithelial Defects Pipeline Therapeutics
6. Persistent Corneal Epithelial Defects Late Stage Products (Phase II/III)
7. Persistent Corneal Epithelial Defects Mid Stage Products (Phase II)
8. Persistent Corneal Epithelial Defects Early Stage Products (Phase I)
9. Persistent Corneal Epithelial Defects Preclinical Stage Products
10. Persistent Corneal Epithelial Defects Therapeutics Assessment
11. Persistent Corneal Epithelial Defects Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Persistent Corneal Epithelial Defects Key Companies
14. Persistent Corneal Epithelial Defects Key Products
15. Persistent Corneal Epithelial Defects Unmet Needs
16 . Persistent Corneal Epithelial Defects Market Drivers and Barriers
17. Persistent Corneal Epithelial Defects Future Perspectives and Conclusion
18. Persistent Corneal Epithelial Defects Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Persistent Corneal Epithelial Defects Market
DelveInsight's 'Persistent Corneal Epithelial Defects Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Persistent Corneal Epithelial Defects Epidemiology
DelveInsight's 'Persistent Corneal Epithelial Defects Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Protein Supplements Market
https://www.delveinsight.com/report-store/protein-supplements-market
Protein Supplements Market By Source (Animal-Based [Whey, Casein, Fish, Eggs, Others], Plant-Based [Soy, Rice, Pea, Spirulina, Others]), By Product Type (Protein Powders, Protein Bars, Ready-To-Drink, And Others), By Application (Sports Nutrition And Functional Foods), By Distribution Channel (Supermarkets And Hypermarkets, E-Commerce, Direct-To-Consumer, Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to the growing consumer awareness of having a protein rich diet,

Proteomics Market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Proteomics Market By Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, And Other], Reagents & Consumables, And Software & Services), By Application (Clinical Diagnostics, Drug Discovery, And Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028.

Infrared Thermometer Market
https://www.delveinsight.com/report-store/infrared-thermometer-market
Infrared Thermometer Market By Product Type (Contact Thermometers And Non-Contact Thermometers), By End-User (Food And Beverage Industry, Electronic Industry, Healthcare Industry, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing need for robust temperature measuring devices in critical industries and rise in the number of infectious diseases across the globe.

Hemoglobinopathies Market
https://www.delveinsight.com/report-store/sport-nutrition-market
Hemoglobinopathies Market By Indication (Thalassemia, Sickle Cell Anaemia, And Others), By Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the increasing prevalence of various hemoglobin disorders and the increasing research & developmental activities concerning to the hemoglobinopathies across the globe

Sport Nutrition Market
https://www.delveinsight.com/report-store/sport-nutrition-market
The Sports Nutrition Market By Product Type (Sports Drinks And Sports Supplements), By Distribution Channels (Hypermarkets & Supermarkets, E-Commerce, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing inclination toward following healthy and active lifestyle and growing importance of sports nutrition among athletes and sportspersons.

Endodontic Devices Market
https://www.delveinsight.com/report-store/endodontic-devices-market
Endodontic Devices Market By Product Type (Instruments [Apex Locators, Endodontic Motors, Endodontic Scalers, Endodontic Lasers, Handpieces, Machine-Assisted Obturation Systems, And Others], Consumables [Obturation, Access Cavity Preparation, Shaping And Cleaning]), By End-User (Dental Hospitals, Dental Clinics, And Others), and by geography is estimated to register growth at a remarkable CAGR during the forecast period from 2023-2028 owing to the rising patient pool associated with dental disorders, poor oral health, leading to increased number of root canal treatments, the increasing population opting for dental aesthetics, among others across the globe.

Chemotherapy Drugs Market https://www.delveinsight.com/report-store/chemotherapy-drugs-market
Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By Route Of Administration (Oral And Parenteral), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of different cancer types and increasing pharmaceutical trials for chemotherapy drugs.

Connected Drug Delivery Devices Market
https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market
Connected Drug Delivery Devices Market By Product (Connected Sensors [Connected Inhaler Sensors And Connectable Injection Sensors] And Integrated Connected Devices [Connected Inhaler Devices And Connected Injection Devices], By Technology (Bluetooth, Near-Field Communication (NFC), And Others), By End-User (Healthcare Providers And Homecare), And by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chronic diseases such as diabetes and improving healthcare it infrastructure across the globe.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.